 It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S.It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.Tropisetron acts as both a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist.